At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.
A large pharmaceutical company needed to
demonstrate the potential cost savings of placing a new drug on payer formularies.
A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).
A mid-size pharmaceutical
company was interested in
obtaining real-world evidence
demonstrating the safety and
effectiveness of higher dosage
chemotherapy for a labeled
oncology indication.
A client needed to develop an algorithm to identify patients at risk for chronic obstructive pulmonary disease (COPD) exacerbations via structured and unstructured EHR data to help clinicians optimize treatments. Magnolia was able to identify patients more precisely through Deep6 AI data than existing algorithms that use claims data alone.
AMCP Spring 2024 Platinum Poster and Presentation.
AMCP Spring 2024 Platinum Poster.
ISPOR Spring 2024.